Ventilator Associated Pneumonia (VAP) : Sales Revenue Market Share by Companies in 2021

 Elmer Henry
  27th-Aug-2016
 21

ACCESS REPORT @ https://www.wiseguyreports.com/reports/619299-ventilator-associated-pneumonia-vap-pipeline-review-h2-2016

Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2016’, provides an overview of the Ventilator Associated Pneumonia (VAP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP)
- The report reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ventilator Associated Pneumonia (VAP) therapeutics and enlists all their major and minor projects
- The report assesses Ventilator Associated Pneumonia (VAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ventilator Associated Pneumonia (VAP)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/619299-ventilator-associated-pneumonia-vap-pipeline-review-h2-2016

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Ventilator Associated Pneumonia (VAP) Overview 9
Therapeutics Development 10
Pipeline Products for Ventilator Associated Pneumonia (VAP) - Overview 10
Pipeline Products for Ventilator Associated Pneumonia (VAP) - Comparative Analysis 11
Ventilator Associated Pneumonia (VAP) - Therapeutics under Development by Companies 12
Ventilator Associated Pneumonia (VAP) - Therapeutics under Investigation by Universities/Institutes 14
Ventilator Associated Pneumonia (VAP) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Ventilator Associated Pneumonia (VAP) - Products under Development by Companies 19
Ventilator Associated Pneumonia (VAP) - Products under Investigation by Universities/Institutes 20
Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development 21
Achaogen Inc. 21
Adenium Biotech ApS 22
Aridis Pharmaceuticals LLC 23
AstraZeneca Plc 24
Bayer AG 25
Cardeas Pharma Corp. 26
MedImmune, LLC 27
Meiji Seika Pharma Co., Ltd. 28
Merck & Co., Inc. 29
Motif Bio Plc 30
Nabriva Therapeutics AG 31
Savara Inc. 32
Shionogi & Co., Ltd. 33
Tetraphase Pharmaceuticals Inc. 34
Zavante Therapeutics, Inc. 35
Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 41
Assessment by Route of Administration 44
Assessment by Molecule Type 47
Drug Profiles 50
(amikacin sulfate + fosfomycin) - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50

…………….. CONTINUED

GET EXCLUSIVE DISCOUNT @ https://www.wiseguyreports.com/check-discount/619299-ventilator-associated-pneumonia-vap-pipeline-review-h2-2016

Contact Us:

Norah Trent

sales@wiseguyreports.com

+1 646 845 9349 / +44 208 133 9349

www.wiseguyreports.com

Domain: Business
Category: Sales & Marketing
Posted By: Elmer Henry and Contact Elmer Henry

Recent Press Releases

USA RPA market is expected to grow a...

According to the recently published report by BlueWeave Consulting, Robotics Process Automation is the use of software with applications of artificial intelligence (AI) and machine

20 September, 2019

Global Patch Management Software Mar...

According to BlueWeave Consulting, Patch Management Software Market is anticipated to grow at a significant rate during the forecast period. The market is expected to grow from USD

20 September, 2019

Rubber Bonded Abrasive Market is exp...

The overall rubber bonded abrasive market is expected to grow from USD 1.09 million in 2016 to USD 1.47 million by 2026, at a CAGR of 3.1% from 2016 to 2021. Rubber bonded abrasive

20 September, 2019